204 related articles for article (PubMed ID: 22500122)
1. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
Roberts MH; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
[TBL] [Abstract][Full Text] [Related]
2. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
[TBL] [Abstract][Full Text] [Related]
3. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
4. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
Ismaila A; Corriveau D; Vaillancourt J; Parsons D; Dalal A; Su Z; Sampalis JS
Curr Med Res Opin; 2014 Jul; 30(7):1427-36. PubMed ID: 24666181
[TBL] [Abstract][Full Text] [Related]
5. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
Dalal AA; Shah M; D'Souza AO; Crater GD
Respir Med; 2012 Jun; 106(6):829-37. PubMed ID: 22425138
[TBL] [Abstract][Full Text] [Related]
6. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease.
Chatterjee A; Shah M; D'Souza AO; Bechtel B; Crater G; Dalal AA
Respir Res; 2012 Feb; 13(1):15. PubMed ID: 22340019
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
8. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.
Delea TE; Hagiwara M; Dalal AA; Stanford RH; Blanchette CM
Curr Med Res Opin; 2009 Jan; 25(1):1-13. PubMed ID: 19210134
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
Dalal AA; Candrilli SD; Davis KL
Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD.
Dalal AA; Petersen H; Simoni-Wastila L; Blanchette CM
J Med Econ; 2009; 12(4):339-47. PubMed ID: 19827993
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.
Dalal AA; St Charles M; Petersen HV; Roberts MH; Blanchette CM; Manavi-Zieverink K
Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():179-87. PubMed ID: 20714371
[TBL] [Abstract][Full Text] [Related]
13. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
14. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.
Kern DM; Williams SA; Tunceli O; Wessman C; Zhou S; Pethick N; Elhefni H; Trudo F
Int J Chron Obstruct Pulmon Dis; 2014; 9():775-83. PubMed ID: 25071369
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
[TBL] [Abstract][Full Text] [Related]
16. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM
Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
[TBL] [Abstract][Full Text] [Related]
17. Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment.
Davis JR; Kern DM; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
J Manag Care Spec Pharm; 2016 Mar; 22(3):293-304. PubMed ID: 27003559
[TBL] [Abstract][Full Text] [Related]
18. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease.
Palli SR; Buikema AR; DuCharme M; Frazer M; Kaila S; Juday T
J Comp Eff Res; 2019 Nov; 8(15):1299-1316. PubMed ID: 31559852
[No Abstract] [Full Text] [Related]
19. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol].
García Ruiz AJ; Leiva Fernández F; Martos Crespo F
Arch Bronconeumol; 2005 May; 41(5):242-8. PubMed ID: 15919004
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
Trudo F; Kern DM; Davis JR; Tunceli O; Zhou S; Graham EL; Strange C; Williams SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2055-66. PubMed ID: 26451101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
